You are here:

  1. Home
  2. NICE Guidance
  3. Published Guidance

Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

  • Technology appraisal guidance
  • Reference number: TA1131
  • Published:  12 February 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Declaration of interests
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6420
  5. Topic selection

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 164 KB)

    Published:
    22 January 2026
  • Equality impact assessment (downloadable version) (PDF 129 KB)

    Published:
    22 January 2026
  • Public committee slides (PowerPoint 1.31 MB)

    Published:
    23 January 2026
  • Committee papers (PDF 4.84 MB)

    Published:
    23 January 2026

Declaration of interests

  • Register of interests (PDF 139 KB)

    Published:
    23 January 2026

Invitation to participate

  • Final scope (PDF 161 KB)

    Published:
    20 May 2025
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 413 KB)

    Published:
    20 May 2025
  • Equality impact assessment (scoping) (PDF 147 KB)

    Published:
    20 May 2025
  • Final stakeholder list (PDF 136 KB)

    Published:
    20 May 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6420

  • Draft matrix post referral (PDF 179 KB)

    Published:
    09 December 2024
  • Draft scope post referral (PDF 201 KB)

    Published:
    09 December 2024

Topic selection

  • Topic selection

Back to top